×
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Transient Ischemic Attack Market Analysis

ID: MRFR/Pharma/3590-CR
226 Pages
Rahul Gotadki
July 2019

Transient Ischemic Attack Market Research Report Information by Diagnosis (Imaging Techniques), Treatment (Surgery and Drugs), Age Groups (0–18 years and above), End-User and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Transient Ischemic Attack Market Infographic
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Market Analysis

In-depth Analysis of Transient Ischemic Attack Market Industry Landscape

The market dynamics of transient ischemic attack (TIA), also known as a mini-stroke, are influenced by various factors that impact the diagnosis, treatment, and prevention of this condition. A TIA occurs when blood flow to the brain is temporarily disrupted, often resulting in symptoms similar to those of a stroke, such as weakness, numbness, or difficulty speaking. Despite being temporary, TIAs are warning signs of potential future strokes, making early detection and management crucial.

One of the key drivers of the TIA market is the increasing prevalence of risk factors such as hypertension, diabetes, and obesity. As these risk factors become more prevalent globally, the incidence of TIAs is expected to rise, driving demand for diagnostic tools and treatment options. Moreover, aging populations in many countries contribute to the growing burden of cerebrovascular diseases, including TIAs, further fueling market growth.

Advancements in medical imaging and diagnostic technologies have revolutionized the detection and characterization of TIAs. Imaging modalities such as magnetic resonance imaging (MRI), computed tomography (CT), and ultrasound play a crucial role in diagnosing TIAs and identifying underlying causes such as carotid artery disease or atrial fibrillation. Additionally, point-of-care diagnostic tests enable rapid assessment of patients presenting with TIA symptoms, facilitating prompt treatment and management.

The treatment landscape for TIAs encompasses various therapeutic approaches aimed at preventing recurrent strokes and managing underlying risk factors. Antiplatelet medications such as aspirin and clopidogrel are commonly prescribed to reduce the risk of blood clot formation and subsequent stroke following a TIA. Furthermore, interventions such as carotid endarterectomy or stenting may be recommended to address significant carotid artery stenosis, a common cause of TIAs. Additionally, lifestyle modifications including smoking cessation, dietary changes, and exercise are integral components of TIA management and prevention.

Healthcare policies and reimbursement frameworks also influence the market dynamics of TIAs. Access to timely diagnosis, treatment, and follow-up care is essential for optimizing patient outcomes and reducing the risk of recurrent strokes. Reimbursement policies for diagnostic tests, medications, and procedures vary across different healthcare systems, impacting market access and adoption of TIA management strategies. Moreover, initiatives aimed at raising awareness about TIAs and promoting preventive measures contribute to market dynamics by driving demand for screening programs and educational resources.

Collaboration among stakeholders in the healthcare ecosystem is essential for addressing the multifaceted challenges associated with TIAs. Healthcare providers, including neurologists, primary care physicians, and emergency department personnel, play a critical role in identifying and managing patients with TIAs. Additionally, partnerships between healthcare organizations, research institutions, and pharmaceutical companies drive innovation in TIA diagnostics and therapeutics, leading to improved patient outcomes.

Market dynamics in the TIA space are also influenced by regulatory considerations and technological advancements. Regulatory agencies such as the Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA) in Europe oversee the approval and marketing of medical devices, pharmaceuticals, and interventions for TIA management. Stringent regulatory standards ensure the safety, efficacy, and quality of TIA treatments while also shaping market entry and competition.

Technological innovations continue to drive progress in TIA management, with ongoing research focused on novel diagnostic biomarkers, targeted therapies, and non-invasive treatment modalities. Advances in telemedicine and digital health technologies enable remote monitoring of patients with TIAs, facilitating timely intervention and follow-up care. Furthermore, artificial intelligence and machine learning algorithms hold promise for enhancing risk stratification and personalized treatment approaches for individuals at high risk of recurrent strokes.

Author
Rahul Gotadki
Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch

Leave a Comment

FAQs

At what CAGR is the global transient ischemic attack market projected to grow in the forecast period (2024-2032)?

Transient ischemic attack market projected to grow at approximately 9.24% CAGR during the assessment period (2024-2032).

How much is the global transient ischemic attack market worth in the future?

The valuation of the global transient ischemic attack market is estimated to increase to USD 0.29 Billion by the end of 2032.

What are the major tailwinds pushing the growth of the global transient ischemic attack market?

Rising need for better treatment due to the increasing prevalence of neurological disorders and increasing R&D investments in biotechnology and pharmaceutical sectors are major tailwinds pushing the growth of the global transient ischemic attack market.

Which region holds the largest share in the global transient ischemic attack market?

North America holds the largest share in the global transient ischemic attack market, followed by Europe and the Asia Pacific, respectively.

Who are the top players in the global transient ischemic attack market?

EnteroMedics Inc. (U.S.), ElectroCore Medical LLC (U.S.), LivaNova PLC (U.K), Cyberonics, Inc. (US), NeuroMetrix, Inc.(U.S.), Boston Scientific Corporation (US), Inspire Medical Systems Inc.(U.S.), Electrical Geodesics Inc. (U.S.), ImThera Medical (U.S.), Nihon Kohden Corporation (Japan), Esaote (Italy), Masimo Corporation (U.S.), and Hologic (U.S.), are some of the top players operating in the global transient ischemic attack market.

Market Summary

As per MRFR analysis, the Transient Ischemic Attack Market Size was estimated at 137.57 USD Million in 2024. The Transient Ischemic Attack industry is projected to grow from 146.9 USD Million in 2025 to 252.62 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 5.64 during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Transient Ischemic Attack Market is experiencing significant growth driven by technological advancements and increasing awareness.

  • Technological advancements in diagnostics are enhancing the accuracy of transient ischemic attack detection in North America.
  • The Asia-Pacific region is emerging as the fastest-growing market, driven by rising healthcare investments and awareness initiatives.
  • Atherosclerotic cases represent the largest segment, while embolic cases are witnessing the fastest growth due to evolving medical technologies.
  • The rising incidence of transient ischemic attacks and increased demand for preventive healthcare solutions are key drivers propelling market expansion.

Market Size & Forecast

2024 Market Size 137.57 (USD Million)
2035 Market Size 252.62 (USD Million)
CAGR (2025 - 2035) 5.64%
Largest Regional Market Share in 2024 North America

Major Players

<p>Boehringer Ingelheim (DE), Bristol-Myers Squibb (US), AstraZeneca (GB), Sanofi (FR), Pfizer (US), Roche (CH), Novartis (CH), Johnson & Johnson (US), Merck & Co. (US)</p>

Market Trends

The Transient Ischemic Attack Market is currently experiencing notable developments driven by advancements in medical technology and increasing awareness of stroke prevention. As healthcare systems evolve, there is a growing emphasis on early diagnosis and intervention strategies. This shift is likely to enhance patient outcomes and reduce the long-term impact of transient ischemic attacks. Furthermore, the integration of telemedicine and digital health solutions appears to facilitate timely access to care, which may significantly influence treatment pathways. In addition, the rising prevalence of risk factors such as hypertension and diabetes is contributing to a heightened focus on managing transient ischemic attacks. Healthcare providers are increasingly prioritizing education and preventive measures, which could lead to a more proactive approach in addressing this condition. The market seems poised for growth as stakeholders recognize the importance of comprehensive care models that encompass both acute management and long-term rehabilitation for affected individuals.

Technological Advancements in Diagnostics

Recent innovations in imaging techniques and biomarker identification are enhancing the accuracy of transient ischemic attack diagnoses. These advancements enable healthcare professionals to differentiate between transient ischemic attacks and other neurological events more effectively, potentially leading to improved treatment outcomes.

Increased Focus on Preventive Care

There is a growing emphasis on preventive strategies aimed at reducing the incidence of transient ischemic attacks. Healthcare systems are likely to invest in public health campaigns and educational initiatives that promote awareness of risk factors and encourage lifestyle modifications among at-risk populations.

Integration of Telehealth Solutions

The incorporation of telehealth services into the management of transient ischemic attacks is becoming more prevalent. This trend may facilitate remote monitoring and consultations, allowing for timely interventions and follow-ups, which could ultimately enhance patient care and accessibility.

Transient Ischemic Attack Market Market Drivers

Aging Population

The demographic shift towards an aging population is a crucial factor driving the Global Transient Ischemic Attack Market Industry. As individuals age, the risk of cerebrovascular diseases, including TIAs, escalates. The United Nations projects that by 2030, the global population aged 60 years and older will reach 1.4 billion, creating a larger cohort susceptible to TIAs. This demographic trend necessitates enhanced healthcare services and interventions tailored to older adults, thereby fostering market expansion. The increasing burden of TIAs among the elderly population underscores the importance of developing targeted therapies and preventive measures.

Rising Incidence of Stroke

The increasing prevalence of stroke globally is a pivotal driver for the Global Transient Ischemic Attack Market Industry. As per recent health statistics, stroke remains one of the leading causes of morbidity and mortality worldwide. The World Health Organization indicates that approximately 15 million people suffer from stroke annually, with a significant portion experiencing transient ischemic attacks as precursors. This alarming trend underscores the necessity for enhanced diagnostic and therapeutic interventions, thereby propelling market growth. The Global Transient Ischemic Attack Market is projected to reach 0.12 USD Billion in 2024, reflecting the urgent need for effective management strategies.

Market Trends and Projections

The Global Transient Ischemic Attack Market Industry is witnessing notable trends that indicate a robust growth trajectory. Projections suggest that the market will expand from 0.12 USD Billion in 2024 to 0.38 USD Billion by 2035, reflecting a compound annual growth rate of 11.0% from 2025 to 2035. This growth is driven by various factors, including advancements in medical technology, increased awareness, and an aging population. The market dynamics are influenced by the evolving healthcare landscape, necessitating continuous adaptation by stakeholders to meet the demands of TIA management.

Regulatory Support and Funding

Government initiatives and regulatory support play a vital role in shaping the Global Transient Ischemic Attack Market Industry. Various health authorities are implementing policies aimed at improving stroke care and funding research for innovative treatments. For example, the National Institutes of Health in the United States allocates substantial resources to stroke research, which indirectly benefits TIA management. Such funding encourages the development of new therapies and technologies, thereby enhancing patient care. This supportive regulatory environment is expected to facilitate market growth, as stakeholders are more inclined to invest in TIA-related innovations.

Increased Awareness and Education

Growing awareness regarding transient ischemic attacks and their implications is significantly influencing the Global Transient Ischemic Attack Market Industry. Public health campaigns and educational initiatives by health organizations aim to inform individuals about the symptoms and risks associated with TIAs. This heightened awareness encourages early medical intervention, which is essential for preventing subsequent strokes. As a result, healthcare systems are increasingly prioritizing TIA management, leading to a surge in demand for related services and products. The market is expected to experience a compound annual growth rate of 11.0% from 2025 to 2035, driven by these educational efforts.

Advancements in Medical Technology

Technological innovations in medical devices and diagnostic tools are transforming the landscape of the Global Transient Ischemic Attack Market Industry. The advent of portable imaging technologies and telemedicine solutions facilitates timely diagnosis and treatment, which is crucial for TIA patients. For instance, advanced MRI techniques enable rapid identification of ischemic episodes, thereby improving patient outcomes. Furthermore, the integration of artificial intelligence in predictive analytics is enhancing risk stratification for TIA patients. These advancements not only improve clinical efficacy but also contribute to the anticipated market growth, with projections indicating a rise to 0.38 USD Billion by 2035.

Market Segment Insights

By Type of Transient Ischemic Attack: Atherosclerotic (Largest) vs. Embolic (Fastest-Growing)

<p>In the Transient Ischemic Attack Market, the distribution among types of transient ischemic attacks reveals that atherosclerotic attacks hold the largest market share, primarily due to their prevalence as a result of vascular diseases. Non-atherosclerotic attacks also contribute significantly, while embolic attacks, though currently smaller in share, are gaining attention as a critical area of growth due to increasing awareness and diagnosis. The overall landscape is characterized by a diverse range of causes and implications for treatment strategies.</p>

<p>Atherosclerotic (Dominant) vs. Embolic (Emerging)</p>

<p>The atherosclerotic segment is characterized by its dominance in the Transient Ischemic Attack Market, driven by a high incidence of ischemic events linked to plaque buildup in arteries. This segment benefits from extensive research and treatment protocols in traditional healthcare settings, making it a well-established area of focus for healthcare providers. In contrast, the embolic segment, categorized as emerging, is witnessing rapid developments as healthcare professionals increasingly recognize its critical role in transient ischemic attacks. Advances in diagnostic techniques and evolving therapeutic strategies are contributing to the growth of this segment, positioning it as a vital area of innovation and potential market expansion.</p>

By Symptoms: Sudden Weakness (Largest) vs. Speech Difficulties (Fastest-Growing)

<p>In the Transient Ischemic Attack (TIA) market, the symptom of sudden weakness dominates the segment, capturing the largest share among various manifestations of TIA. This symptom is often the first to be recognized by patients and their caregivers, prompting emergency interventions. Additionally, speech difficulties are emerging as the fastest-growing segment. Increased awareness and rapid identification of this symptom have led to timely diagnosis and treatment, which is crucial for patient outcomes.</p>

<p>Sudden Weakness (Dominant) vs. Speech Difficulties (Emerging)</p>

<p>Sudden weakness is recognized as the dominant symptom in the Transient Ischemic Attack market, prominently affecting functional mobility and patient quality of life. This symptom typically presents as a significant inability to control muscle strength, leading to immediate medical attention. Conversely, speech difficulties have been identified as an emerging symptom that is rapidly gaining attention due to advancements in telemedicine and patient education. This symptom, characterized by slurred or unclear speech, indicates serious neurological impairment and is increasingly prioritized for prompt intervention. Together, these symptoms underscore the critical need for timely diagnosis and treatment in the TIA market.</p>

By Risk Factors: Hypertension (Largest) vs. Diabetes (Fastest-Growing)

<p>In the Transient Ischemic Attack Market, hypertension stands out as the largest risk factor, contributing significantly to the incidence of TIAs. This segment accounts for a substantial proportion of risk factors, highlighting the urgent need for targeted prevention and management strategies. Meanwhile, diabetes, while not as prevalent as hypertension, is emerging as a pivotal factor that poses unique risks and is experiencing rapid growth among populations, particularly with the rising prevalence of lifestyle diseases.</p>

<p>Hypertension (Dominant) vs. Diabetes (Emerging)</p>

<p>Hypertension is recognized as the dominant risk factor for transient ischemic attacks, reflecting a widespread health challenge that affects millions globally. Its management is crucial as high blood pressure can lead to severe vascular complications, including TIAs. Conversely, diabetes is rapidly gaining attention as an emerging risk factor, driven by increasing obesity rates and sedentary lifestyles. The link between poorly managed diabetes and TIAs suggests that patients with this condition face compounding risks, necessitating a proactive approach to intervention and care. As awareness and education around diabetes continues to grow, so too will its implications within the TIA market.</p>

By Diagnosis Method: CT Scan (Largest) vs. MRI (Fastest-Growing)

<p>In the Transient Ischemic Attack Market, the diagnosis methods are essential for timely and accurate patient assessment. Among the available methods, CT Scans hold the largest share, proving to be the traditional choice due to their rapid imaging capabilities and widespread availability. In contrast, MRI is quickly gaining traction as a preferred option due to its superior imaging quality of brain tissues, which plays a critical role in diagnosing transient ischemic attacks.</p>

<p>CT Scan (Dominant) vs. MRI (Emerging)</p>

<p>CT Scans have long been the cornerstone of emergency diagnosis in transient ischemic attacks, providing fast and accessible imaging that supports rapid decision-making. They excel in identifying acute hemorrhagic events, which is crucial in emergent care. Meanwhile, MRI technology represents the emerging frontier in this market, offering detailed insights into cerebral ischemia that other methods cannot compete with. As healthcare institutions increasingly adopt advanced imaging techniques, MRI's superior specificity and sensitivity are leading to increased usage, making it a promising tool in the diagnostic arsenal for transient ischemic attacks.</p>

By Treatment Options: Antiplatelet Therapy (Largest) vs. Anticoagulants (Fastest-Growing)

<p>In the Transient Ischemic Attack (TIA) market, Antiplatelet Therapy holds the largest share, being the most commonly prescribed treatment for preventing future strokes. This therapy primarily focuses on preventing the formation of blood clots, thus mitigating the risk associated with TIAs. In comparison, Anticoagulants are witnessing rapid growth, gaining traction among healthcare providers due to their efficacy in managing complex cases and their role in secondary stroke prevention. Growth trends indicate a shift towards more integrated treatment strategies that include both Antiplatelet and Anticoagulant therapies, as well as individual lifestyle modifications. With increasing awareness about stroke risks and preventive measures, more patients are being guided towards comprehensive care that includes lifestyle changes, positioned to complementary enhance therapy outcomes.</p>

<p>Antiplatelet Therapy (Dominant) vs. Lifestyle Modifications (Emerging)</p>

<p>Antiplatelet Therapy is recognized as the dominant player in the TIA treatment landscape, primarily due to its longstanding clinical use and robust clinical guidelines endorsing its use. It effectively reduces thromboembolic events, making it a cornerstone in managing TIA patients. Meanwhile, Lifestyle Modifications are emerging as vital components in ongoing TIA management. These modifications focus on dietary changes, regular physical activity, and smoking cessation, addressing the underlying risk factors contributing to TIAs. While Lifestyle Modifications do not provide an immediate therapeutic option, they play a crucial role in long-term stroke prevention, thus becoming integral to patient education and self-management techniques.</p>

Get more detailed insights about Transient Ischemic Attack Market Research Report - Global Forecast till 2035

Regional Insights

North America : Market Leader in TIA Solutions

North America is poised to maintain its leadership in the Transient Ischemic Attack (TIA) market, holding a significant market share of 68.78% as of 2024. The region's growth is driven by increasing awareness of stroke prevention, advancements in medical technology, and supportive healthcare policies. Regulatory bodies are actively promoting initiatives to enhance patient outcomes, which further fuels demand for innovative treatment options. The competitive landscape in North America is robust, featuring key players such as Boehringer Ingelheim, Bristol-Myers Squibb, and Pfizer. The U.S. stands out as the leading country, supported by a well-established healthcare infrastructure and significant investments in research and development. This environment fosters innovation, enabling companies to introduce new therapies that address the needs of TIA patients effectively.

Europe : Emerging Market with Growth Potential

Europe is witnessing a growing interest in the Transient Ischemic Attack (TIA) market, with a market size of €40.27 million in 2024. The region benefits from a strong regulatory framework that encourages research and development in stroke prevention and treatment. Increased funding for healthcare initiatives and a rising aging population are key drivers of market growth, leading to heightened demand for effective TIA management solutions. Leading countries in Europe include Germany, France, and the UK, where major pharmaceutical companies like AstraZeneca and Sanofi are actively involved. The competitive landscape is characterized by collaborations and partnerships aimed at enhancing treatment options. The European Medicines Agency continues to support innovative therapies, ensuring that patients have access to the latest advancements in TIA care.

Asia-Pacific : Rapidly Growing Healthcare Sector

The Asia-Pacific region is emerging as a significant player in the Transient Ischemic Attack (TIA) market, with a market size of $24.52 million in 2024. Factors such as increasing healthcare expenditure, rising awareness of stroke risks, and government initiatives to improve healthcare access are driving market growth. The region's diverse population and varying healthcare systems present unique challenges and opportunities for TIA management. Countries like Japan, China, and Australia are at the forefront of this growth, with key players such as Roche and Novartis expanding their presence. The competitive landscape is evolving, with a focus on localized treatment options and partnerships with healthcare providers. As regulatory bodies in the region enhance their frameworks, the market is expected to see further advancements in TIA therapies.

Middle East and Africa : Emerging Market with Challenges

The Middle East and Africa (MEA) region is gradually developing its Transient Ischemic Attack (TIA) market, currently valued at $4.0 million in 2024. The growth is hindered by limited healthcare infrastructure and varying levels of awareness regarding stroke prevention. However, increasing government initiatives aimed at improving healthcare access and education are beginning to change this landscape, fostering demand for TIA treatments. Countries like South Africa and the UAE are leading the way in TIA management, with efforts to enhance healthcare systems and patient education. The competitive landscape is still nascent, with few key players actively involved. As regulatory bodies focus on improving healthcare standards, the potential for growth in the TIA market in MEA is becoming more apparent.

Key Players and Competitive Insights

The Transient Ischemic Attack Market is characterized by a dynamic competitive landscape, driven by an increasing prevalence of cerebrovascular diseases and a growing emphasis on early intervention strategies. Key players such as Boehringer Ingelheim (DE), Bristol-Myers Squibb (US), and AstraZeneca (GB) are strategically positioned to leverage their extensive research capabilities and innovative product pipelines. These companies are focusing on enhancing their therapeutic offerings through partnerships and collaborations, which collectively shape a competitive environment that is increasingly reliant on advanced treatment modalities and patient-centric solutions.

In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance operational efficiency and reduce costs. The market structure appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies like Sanofi (FR) and Pfizer (US) is notable, as they continue to expand their portfolios and strengthen their market presence through strategic acquisitions and product launches.

In November 2025, Boehringer Ingelheim (DE) announced a collaboration with a leading digital health company to develop a mobile application aimed at improving patient adherence to prescribed therapies for transient ischemic attacks. This strategic move underscores the company's commitment to integrating technology into patient care, potentially enhancing treatment outcomes and fostering patient engagement.

In October 2025, Bristol-Myers Squibb (US) launched a new clinical trial focused on a novel anticoagulant specifically designed for patients at risk of transient ischemic attacks. This initiative not only reflects the company's dedication to innovation but also positions it to capture a significant share of the market by addressing unmet medical needs in this patient population.

In September 2025, AstraZeneca (GB) expanded its partnership with a prominent research institution to explore the genetic factors associated with transient ischemic attacks. This collaboration is likely to yield valuable insights that could inform the development of targeted therapies, thereby enhancing AstraZeneca's competitive edge in the market.

As of December 2025, current competitive trends indicate a strong shift towards digitalization, sustainability, and the integration of artificial intelligence in treatment protocols. Strategic alliances are increasingly shaping the landscape, allowing companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve, with a pronounced shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability, ultimately enhancing patient care and treatment efficacy.

Key Companies in the Transient Ischemic Attack Market market include

Industry Developments

Future Outlook

Transient Ischemic Attack Market Future Outlook

<p>The Transient Ischemic Attack Market is projected to grow at a 5.64% CAGR from 2024 to 2035, driven by advancements in diagnostics, increased awareness, and improved treatment options.</p>

New opportunities lie in:

  • <p>Development of AI-driven diagnostic tools for early detection.</p>
  • <p>Expansion of telehealth services for remote patient monitoring.</p>
  • <p>Investment in personalized medicine approaches for tailored therapies.</p>

<p>By 2035, the market is expected to achieve substantial growth, reflecting enhanced treatment modalities and increased patient engagement.</p>

Market Segmentation

Transient Ischemic Attack Market Symptoms Outlook

  • Sudden Weakness
  • Speech Difficulties
  • Vision Problems
  • Dizziness
  • Confusion

Transient Ischemic Attack Market Risk Factors Outlook

  • Hypertension
  • Diabetes
  • High Cholesterol
  • Smoking
  • Obesity

Transient Ischemic Attack Market Diagnosis Method Outlook

  • CT Scan
  • MRI
  • Ultrasound
  • Blood Tests

Transient Ischemic Attack Market Treatment Options Outlook

  • Antiplatelet Therapy
  • Anticoagulants
  • Lifestyle Modifications
  • Surgery

Transient Ischemic Attack Market Type of Transient Ischemic Attack Outlook

  • Non-Atherosclerotic
  • Atherosclerotic
  • Embolic

Report Scope

MARKET SIZE 2024137.57(USD Million)
MARKET SIZE 2025146.9(USD Million)
MARKET SIZE 2035252.62(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)5.64% (2024 - 2035)
REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR2024
Market Forecast Period2025 - 2035
Historical Data2019 - 2024
Market Forecast UnitsUSD Million
Key Companies ProfiledBoehringer Ingelheim (DE), Bristol-Myers Squibb (US), AstraZeneca (GB), Sanofi (FR), Pfizer (US), Roche (CH), Novartis (CH), Johnson & Johnson (US), Merck & Co. (US)
Segments CoveredType of Transient Ischemic Attack, Symptoms, Risk Factors, Diagnosis Method, Treatment Options
Key Market OpportunitiesAdvancements in telemedicine enhance early detection and management of Transient Ischemic Attacks.
Key Market DynamicsRising demand for innovative therapies drives competition and regulatory scrutiny in the Transient Ischemic Attack market.
Countries CoveredNorth America, Europe, APAC, South America, MEA

FAQs

At what CAGR is the global transient ischemic attack market projected to grow in the forecast period (2024-2032)?

Transient ischemic attack market projected to grow at approximately 9.24% CAGR during the assessment period (2024-2032).

How much is the global transient ischemic attack market worth in the future?

The valuation of the global transient ischemic attack market is estimated to increase to USD 0.29 Billion by the end of 2032.

What are the major tailwinds pushing the growth of the global transient ischemic attack market?

Rising need for better treatment due to the increasing prevalence of neurological disorders and increasing R&amp;D investments in biotechnology and pharmaceutical sectors are major tailwinds pushing the growth of the global transient ischemic attack market.

Which region holds the largest share in the global transient ischemic attack market?

North America holds the largest share in the global transient ischemic attack market, followed by Europe and the Asia Pacific, respectively.

Who are the top players in the global transient ischemic attack market?

EnteroMedics Inc. (U.S.), ElectroCore Medical LLC (U.S.), LivaNova PLC (U.K), Cyberonics, Inc. (US), NeuroMetrix, Inc.(U.S.), Boston Scientific Corporation (US), Inspire Medical Systems Inc.(U.S.), Electrical Geodesics Inc. (U.S.), ImThera Medical (U.S.), Nihon Kohden Corporation (Japan), Esaote (Italy), Masimo Corporation (U.S.), and Hologic (U.S.), are some of the top players operating in the global transient ischemic attack market.

  1. Report Prologue
  2. Executive Summary
  3. Market Introduction
    1. Definition 26
    2. Scope Of Study 26
    3. List Of Assumptions 26
    4. Market Structure 27
  4. Research Methodology
    1. Research Process 29
    2. Primary Research 30
    3. Secondary Research 31
    4. Market Size Estimation 32
    5. Forecast Model 32
  5. Market Dynamics
    1. Introduction 34
    2. Drivers 35
      1. Increasing Preference For Minimally Invasive Procedures 35
      2. Rising Prevalence Of Chronic Disorders 36
      3. Improvement In Reimbursement Scenario 37
      4. Rising Geriatric Population 38
    3. Restraints 39
      1. Rising Treatment Cost And Hospital Stay 39
      2. Lack Of Skilled Physicians 40
    4. Opportunities 41
      1. New Advancements In Catheterization Devices 41
      2. Guide Wire Assisted Surgery In Elderly Population 41
    5. Mega Trends 41
      1. Telemedicine 41
    6. Macroeconomic Indicators 41
    7. Technology Trends & Assessment 42
  6. Market Factor Analysis
    1. Porter’s Five Forces Model 44
      1. Threat Of New Entrants 44
      2. Bargaining Power Of Suppliers 44
      3. Threat Of Substitutes 45
      4. Bargaining Power Of Buyers 45
      5. Intensity Of Rivalry 45
    2. Supply Chain Analysis 46
      1. Research &Development 46
      2. Manufacturing 46
      3. Distribution 46
      4. Marketing & Sales 47
      5. Post-Sales Monitoring 47
    3. Demand & Supply: Gap Analysis 47
    4. Pricing Analysis 47
    5. Investment Feasibility Analysis 47
  7. Global Transient Ischemic Attack Market, By Diagnosis
    1. Introduction 49
    2. Imaging Techniques 49
      1. Computed Tomography (CT) Scan 51
      2. Carotid Duplex Scanning 51
      3. Magnetic Resonance Imaging 52
      4. Echocardiography 52
  8. Global Transient Ischemic Attack Market, By Treatment
    1. Introduction 54
    2. Surgery 54
    3. Drugs 54
      1. Surgery 55
      2. Drugs 56
  9. Global Transient Ischemic Attack Market, By Age Groups
    1. Introduction 62
    2. 0–18 Years 62
    3. 19–40 Years (Millennial) 62
    4. 41–60 Years 62
    5. 60+ Years 63
      1. 0-18 Years 64
      2. 19-40 Years 65
      3. 41-60 Years 65
      4. 60+ Years 65
  10. Global Transient Ischemic Attack Market, By End-User
    1. Introduction 67
    2. Hospitals & Clinics 67
    3. Diagnostic Centers 67
    4. Research Laboratories 68
      1. Hospitals 69
      2. Diagnostic Centers 70
      3. Research Laboratories 70
  11. Global Transient Ischemic Attack Market, By Region
    1. Introduction 72
    2. Americas 73
      1. North America 78
      2. South America 90
    3.  
    4. Europe 94
      1. Western Europe 99
      2. Eastern Europe 127
    5. Asia Pacific 131
      1. Asia Pacific 132
      2. Japan 136
      3. China 140
      4. India 144
      5. Australia 148
      6. Republic Of Korea 152
      7. Rest Of Asia Pacific 156
    6. The Middle East & Africa 160
      1. Middle East And Africa 161
      2. United Arab Emirates 164
      3. Saudi Arabia 168
      4. Rest Of Middle East & Africa 172
  12. Competitive Landscape
    1. Company Market Share Analysis 177
      1. Introduction 177
    2. Company Share Analysis 178
    3. Recent Developments, 2013–2018 179
  13. Company Profiles
    1. Koninklijke Philips N.V. 184
      1. Company Overview 184
      2. Financial Overview 184
      3. Products Offering 185
      4. Key Developments 185
      5. SWOT Analysis 185
      6. Key Strategy 186
    2. Stryker Corporation 187
      1. Company Overview 187
      2. Financial Overview 187
      3. Products Offering 188
      4. Key Developments 188
      5. SWOT Analysis 189
      6. Key Strategy 189
    3. Johnson & Johnson Services Inc. 190
      1. Company Overview 190
      2. Financial Overview 190
      3. Products Offering 191
      4. Key Developments 191
      5. SWOT Analysis 192
      6. Key Strategy 192
    4. Boston Scientific Corporation 193
      1. Company Overview 193
      2. Financial Overview 193
      3. Products Offering 194
      4. Key Developments 195
      5. SWOT Analysis 195
      6. Key Strategy 195
    5. Sanofi 196
      1. Company Overview 196
      2. Financial Overview 196
      3. Products Offering 197
      4. Key Developments 197
      5. SWOT Analysis 197
      6. Key Strategy 197
    6. Bayer AG 198
      1. Company Overview 198
      2. Financial Overview 198
      3. Products Offering 199
      4. Key Developments 199
      5. SWOT Analysis 199
      6. Key Strategy 199
    7. Pfizer Inc. 200
      1. Company Overview 200
      2. Financial Overview 200
      3. Products Offering 201
      4. Key Developments 201
      5. SWOT Analysis 201
      6. Key Strategy 201
    8. Siemens AG 202
      1. Company Overview 202
      2. Financial Overview 202
      3. Products Offering 203
      4. Key Developments 203
      5. SWOT Analysis 203
      6. Key Strategy 203
    9. F. Hoffmann-La Roche AG 204
      1. Company Overview 204
      2. Financial Overview 204
      3. Products Offering 205
      4. Key Developments 205
      5. SWOT Analysis 205
      6. Key Strategy 205
    10. GE Healthcare 206
      1. Company Overview 206
      2. Financial Overview 206
      3. Products Offering 207
      4. Key Developments 207
      5. SWOT Analysis 207
      6. Key Strategy 207
    11. Penumbra, Inc. 208
      1. Company Overview 208
      2. Financial Overview 208
      3. Products Offering 209
      4. Key Developments 209
      5. SWOT Analysis 209
      6. Key Strategy 210
    12. Medtronic PLC 211
      1. Company Overview 211
      2. Financial Overview 211
      3. Products Offering 212
      4. Key Developments 212
      5. SWOT Analysis 212
      6. Key Strategy 213
    13. Abbott Laboratories 214
      1. Company Overview 214
      2. Financial Overview 214
      3. Products Offering 215
      4. Key Developments 215
      5. SWOT Analysis 216
      6. Key Strategy 216
    14. Merck & Co., Inc. 217
      1. Company Overview 217
      2. Financial Overview 217
      3. Products Offering 218
      4. Key Developments 218
      5. SWOT Analysis 218
      6. Key Strategy 218
    15. Boehringer Ingelheim GmbH 219
      1. Company Overview 219
      2. Financial Overview 219
      3. Products Offering 220
      4. Key Developments 220
      5. SWOT Analysis 220
      6. Key Strategy 220
  14. Conclusion
    1. Key Findings 222
      1. CEO’s Viewpoint 222
      2. Unmet Needs 222
      3. Key Companies To Watch 222
      4. Prediction 222
  15. Appendix
    1. Discussion Blue Print 224
    2. References 225
  16. List Of Tables
  17. MARKET SYNOPSIS 24
  18. LIST OF ASSUMPTIONS 26
  19. PRIMARY INTERVIEWS 30
  20. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 50
  21. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUES, 2020–2027 (USD MILLION) 50
  22. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR IMAGING TECHNIQUES, BY COMPUTED TOMOGRAPHY (CT) SCAN,
  23. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR IMAGING TECHNIQUES, BY CAROTID DUPLEX SCANNING,
  24. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR IMAGING TECHNIQUES, BY MAGNETIC RESONANCE IMAGING,
  25. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR IMAGING TECHNIQUES, BY ECHOCARDIOGRAPHY,
  26. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 55
  27. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY SURGERY, 2020–2027 (USD MILLION) 55
  28. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 56
  29. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUG, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 56
  30. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
  31. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTIPLATELETS, BY CLOPIDOGREL, 2020–2027 (USD MILLION) 57
  32. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTIPLATELETS, BY ASPIRIN, 2020–2027 (USD MILLION) 57
  33. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 57
  34. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR HEPARINS, BY ENOXAPARIN, 2020–2027 (USD MILLION) 58
  35. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR HEPARINS, BY DALTEPARIN, 2020–2027 (USD MILLION) 58
  36. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
  37. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR FIBRINOLYTICS, BY TENECTEPLASE, 2020–2027 (USD MILLION) 59
  38. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR FIBRINOLYTICS, BY ALTEPLASE 2020–2027 (USD MILLION) 59
  39. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 59
  40. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTIHYPERTENSIVE AGENTS, BY PRAZOSIN,
  41. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTIHYPERTENSIVE AGENTS, BY MOXONIDINE,
  42. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUPS, 2020–2027 (USD MILLION) 63
  43. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR AGE GROUP, BY 0-18 YEARS, 2020–2027 (USD MILLION) 64
  44. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR AGE GROUP, BY 19-40 YEARS, 2020–2027 (USD MILLION) 65
  45. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR AGE GROUP, BY 41-60 YEARS, 2020–2027 (USD MILLION) 65
  46. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR AGE GROUP, BY 60+ YEARS, 2020–2027 (USD MILLION) 65
  47. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 68
  48. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR HOSPITALS, BY REGION, 2020–2027 (USD MILLION) 69
  49. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2020–2027 (USD MILLION) 70
  50. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR RESEARCH LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 70
  51. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY REGION, 2020–2027 (USD MILLION) 72
  52. AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET, BY REGION, 2020–2027 (USD MILLION) 73
  53. AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 74
  54. AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 74
  55. AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,, 2020–2027 (USD MILLION) 74
  56. AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 75
  57. AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 75
  58. AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
  59. AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,
  60. AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
  61. AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 76
  62. AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 77
  63. AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 77
  64. NORTH AMERICA: TRANSIENT ISCHEMIC ATTACK MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 78
  65. NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 78
  66. NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE,
  67. NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 79
  68. NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 79
  69. NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,
  70. NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
  71. NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,
  72. NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
  73. NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS,
  74. NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 81
  75. NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 82
  76. U.S. TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 82
  77. U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 82
  78. U.S. TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,, 2020–2027 (USD MILLION) 83
  79. U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 83
  80. U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS 2020–2027 (USD MILLION) 83
  81. U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
  82. U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 84
  83. U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
  84. U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 85
  85. U.S. TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 85
  86. U.S. TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 85
  87. CANADA TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 86
  88. CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 86
  89. CANADA TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,, 2020–2027 (USD MILLION) 86
  90. CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 87
  91. CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 87
  92. CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
  93. CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 88
  94. CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
  95. CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 88
  96. CANADA TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 89
  97. CANADA TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 89
  98. SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 90
  99. SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE,
  100. SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 90
  101. SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 91
  102. SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,
  103. SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
  104. SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,
  105. SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
  106. SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS,
  107. SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 93
  108. SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 93
  109. EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 94
  110. EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 95
  111. EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 95
  112. EUROPE TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,, 2020–2027 (USD MILLION) 95
  113. EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 96
  114. EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 96
  115. EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
  116. EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 97
  117. EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
  118. EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 97
  119. EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 98
  120. EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 98
  121. WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 99
  122. WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE,
  123. WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 99
  124. WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 100
  125. WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,
  126. WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
  127. WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,
  128. WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
  129. WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS,
  130. WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 102
  131. WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 102
  132. GERMANY TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 103
  133. GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 103
  134. GERMANY TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 103
  135. GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 104
  136. GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 104
  137. GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
  138. GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,
  139. GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
  140. GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 105
  141. GERMANY TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 106
  142. GERMANY TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 106
  143. FRANCE TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 107
  144. FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 107
  145. FRANCE TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 107
  146. FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 108
  147. FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 108
  148. FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
  149. FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 109
  150. FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
  151. FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 109
  152. FRANCE TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 110
  153. FRANCE TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 110
  154. U.K TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 111
  155. U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 111
  156. U.K TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,, 2020–2027 (USD MILLION) 111
  157. U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 112
  158. U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 112
  159. U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS, 2020–2027 (USD MILLION) 112
  160. U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 113
  161. U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS, 2020–2027 (USD MILLION) 113
  162. U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 113
  163. U.K TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 114
  164. U.K TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 114
  165. ITALY TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 115
  166. ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 115
  167. ITALY TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 115
  168. ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 116
  169. ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS 2020–2027 (USD MILLION) 116
  170. ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
  171. ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 117
  172. ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
  173. ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 117
  174. ITALY TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 118
  175. ITALY TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 118
  176. SPAIN TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 119
  177. SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 119
  178. SPAIN TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,, 2020–2027 (USD MILLION) 119
  179. SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 120
  180. SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 120
  181. SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
  182. SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 121
  183. SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
  184. SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 121
  185. SPAIN TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 122
  186. SPAIN TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 122
  187. REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 123
  188. REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE,
  189. REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 123
  190. REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 124
  191. REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,
  192. REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
  193. REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,
  194. REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
  195. REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS,
  196. REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 126
  197. REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 126
  198. EASTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 127
  199. EASTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE,
  200. EASTERN EUROPE TRANSIENT ISCHE

Transient Ischemic Attack Market Segmentation

Market Segmentation Overview

  • Detailed segmentation data will be available in the full report
  • Comprehensive analysis by multiple parameters
  • Regional and country-level breakdowns
  • Market size forecasts by segment
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Related Reports

Regional Reports
Country Reports

Customer Strories

Customer Stories
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓